The herpes zoster vaccine (Zostavax) has been shown to greatly decrease the risk of shingles. The vaccine is approved by the Food and Drug Administration for adults age 50 and older and is recommended for all adults 60 and older who aren't allergic to the vaccine and who don't take immune-suppressing medications.
Sept. 16, 2015
- Bajwa ZH, et al. Postherpetic neuralgia. http://www.uptodate.com/home. Accessed Sept. 1, 2015.
- Tseng HF, et al. Zoster vaccine and the risk of postherpetic neuralgia in patients who developed herpes zoster despite having received the zoster vaccine. Journal of Infectious Diseases. In press. Accessed Sept. 1, 2015.
- Johnson RW, et al. Postherpetic neuralgia. The New England Journal of Medicine. 2014;371:1526.
- Dubinsky RM, et al. Practice parameter: Treatment of postherpetic neuralgia. American Academy of Neurology. 2004;63:959.
- Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clinic Proceedings. 2009;84:274.
- Important drug warning. U.S. Food and Drug Administration. http://google2.fda.gov/search?q=cache:EKB1SS0qgzQJ:www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm213266.pdf+tramadol+suicide+risk&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&access=p&oe=UTF-8. Accessed Sept. 3, 2015.